Autopsy report · NCT02220738

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors

“Slow subject enrollment”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 1 year 6 months before it stopped.
• 19 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

AbbVie

Sponsor type

Industry

Conditions

Alzheimer's Disease

Interventions

ABT-957; Placebo for ABT-957

Participants

19

Sites

4

Countries

United States

Trials that died the same way

• Clinical Performance of the MaterniT21 PLUS LDT in Multiple Gestation Pregnancies
  “Slow enrollment of eligible subjects” (93% match in meaning)
• Effectiveness of ROTEM-based Coagulation Surveillance on Reducing Blood Product Utilization During Complex Spine Surgery
  “Slow enrollment” (92% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.